



Press release

GenSight Biologics wins 2016 Deloitte Technology Fast 50 “Biotech of the Future” Award for the Paris region

Paris, France, November 8, 2016 – GenSight Biologics (Euronext: SIGHT, FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, yesterday received the “Biotech of the Future” Award at the 16th edition of the Deloitte Technology Fast 50 in Paris.

Created in 2001, Deloitte Technology Fast 50 promotes and encourages, year after year, the development of companies that combine innovation and fast growth in high-tech.

GenSight Biologics received the “Biotech of the Future” Award recognizing the success of its recent fund raisings. The Company completed a Series B financing round of €32 million in July 2015, before raising €45 million in the context of its successful Initial Public Offering on Euronext Paris in July 2016. These proceeds allowed the Company to advance the development of its product candidates, and notably allow it to complete GS010’s clinical development, currently in Phase III.

Bernard Gilly, Chief Executive Officer of GenSight Biologics, commented: *“We are very proud to receive this award that recognizes the work and commitment of our team. This prize is an encouragement to pursue the development of safe, efficient and innovative therapies for patients.”*

Contacts

GenSight Biologics

Thomas Gidoïn
Chief Financial Officer
ir@gensight-biologics.com
+33 (0)1 76 21 72 20

NewCap

Relations investisseurs
Florent Alba
gensight@newcap.eu
+33 (0)1 44 71 98 55

RooneyPartners

Media Relations
Marion Janic
mjanic@rooneyco.com
+1-212-223-4017

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics’ pipeline leverages two core technology platforms, Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible vision loss in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to offer patients a sustainable functional visual recovery with a single treatment to each eye through an intravitreal injection.